Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 164
- 试验地点
- 4
- 主要终点
- Drug concentration in infant plasma
研究概览
简要总结
The purpose of this study is to characterize the pharmacokinetics (PK) of understudied drugs administered to lactating women, receiving antiretroviral drugs per SOC as prescribed by their healthcare provider, and their co-enrolled infants ≤180 days of age who receive maternal breastmilk.
详细描述
Prospective, single-site, open label, PK and safety study. Co-enrollment of lactating women ≥18 years of age receiving drugs of interest (DOIs) per standard of care (SOC), as prescribed by their healthcare providers, and their infants who receive maternal breastmilk ≤180 days postpartum.
To understand drug transfer into breastmilk and determine subsequent infant exposure, biological samples will be collected from lactating women (blood and breastmilk) and infants (blood). The opportunistic design of this study will allow for a minimal risk study, an expanded enrollment net, evaluation of antiretroviral drugs, and capitalization of procedures performed per SOC to maximize study efficiency and data collection and minimize potential risk to participants. The data collected through this initiative will provide valuable PK, dosing, and safety information for drugs in this vulnerable population in order to inform public health.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Drug of Interest
Lactating moms receiving one or more antiretroviral drugs and their breastmilk fed infants per standard of care.
干预措施: Dolutegravir (Drug)
Drug of Interest
Lactating moms receiving one or more antiretroviral drugs and their breastmilk fed infants per standard of care.
干预措施: Lamivudine (Drug)
Drug of Interest
Lactating moms receiving one or more antiretroviral drugs and their breastmilk fed infants per standard of care.
干预措施: Emtricitabine (Drug)
Drug of Interest
Lactating moms receiving one or more antiretroviral drugs and their breastmilk fed infants per standard of care.
干预措施: Tenofovir Disoproxil Fumarate (Drug)
结局指标
主要结局
Drug concentration in infant plasma
时间窗: Baseline
Drug concentration of a DOI in infant plasma
Estimated daily infant dose
时间窗: Baseline
The drug exposure of selected DOIs will be evaluated using the estimated daily infant dose
Drug concentration in maternal plasma
时间窗: Baseline
Drug concentration of a DOI in maternal plasma
Drug concentration in maternal breastmilk
时间窗: Baseline
Drug concentration of a DOI in maternal breastmilk
Milk/Plasma ratio
时间窗: Baseline
The drug exposure of selected DOIs will be evaluated using milk/plasma ratio
Relative infant dose
时间窗: Baseline
The drug exposure of selected DOIs will be evaluated using relative infant dose
Infant/maternal exposure ratio
时间窗: Baseline
The drug exposure of selected DOIs will be evaluated using infant/maternal exposure ratio
次要结局
未报告次要终点
